证券代码：301509 证券简称：金凯生科 公告编号：2024-026 金凯（辽宁）生命科技股份有限公司 关于变更公司注册资本、修订《公司章程》 并办理工商登记的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）于2024年8月24日召开 第二届董事会第四次会议、第二届监事会第四次会议，审议通过了《关于变更公司注 册资本、修订<公司章程>并办理工商登记的议案》，同意公司根据2024年7月1日生效 施行的《中华人民共和国公司法》并结合公司2023年度权益分派情况变更公司注册资 本、相应修订《公司章程》并办理相关工商变更登记事项。现将相关情况公告如下： 一、公司注册资本变更情况 公司于2024年3月30日召开了第二届董事会第二次会议和第二届监事会第二次会议， 并于2024年4月23日召开了2023年度股东大会，审议通过了《关于<2023年度利润分配 方案>的议案》，本次权益分派以截至2023年12月31日公司总股本86,033,335股为基数， 向全体股东每10股派发现金红利人民币8.00元（含税），合 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[8]. - The company's operating revenue for the reporting period was ¥261,993,494.68, a decrease of 39.36% compared to the same period last year[13]. - Net profit attributable to shareholders was ¥32,091,742.08, down 71.32% year-over-year[13]. - Basic and diluted earnings per share were both ¥0.27, reflecting a decline of 78.23% compared to the previous year[13]. - The total profit for the first half of 2024 was CNY 34,262,641.95, down from CNY 126,814,616.98 in the same period of 2023, reflecting a decrease of approximately 73.0%[99]. - The net cash flow from operating activities surged by 114.94% to ¥65.27 million, primarily due to the recovery of significant accounts receivable from previous periods[24]. - The company reported a significant decrease in investment cash flow, dropping by 768.34% to -¥110.43 million, attributed to the use of idle funds for financial management[24]. Market Outlook and Strategy - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20% to 30% based on current market trends and demand[8]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share in the region by 2025[8]. - A strategic acquisition of a local biotech firm is in progress, which is expected to enhance the company's R&D capabilities and product offerings[8]. - The company is focusing on enhancing its digital marketing strategies, aiming for a 30% increase in online sales channels by the end of 2024[8]. - The company faces risks related to service decoupling and demand fluctuations, with 80% of its revenue coming from overseas markets[44]. - To mitigate risks, the company is optimizing customer development strategies and enhancing cooperation with both large multinational and innovative small to medium-sized pharmaceutical companies[44]. Research and Development - New product development is underway, with three innovative drugs expected to enter clinical trials by the end of 2024, enhancing the company's product pipeline[8]. - Research and development expenses increased by 23.59% to ¥16.93 million from ¥13.70 million in the previous year, indicating a commitment to innovation despite overall revenue decline[24]. - The company provides CDMO services for global pharmaceutical clients, focusing on small molecule drug development and production[18]. - The company has developed various technical capabilities, including fluorination and chiral synthesis, to enhance production efficiency and reduce costs[18]. Environmental and Safety Management - The company is classified as a key pollutant discharge unit, adhering to various environmental protection laws and standards[52]. - The company has a valid pollutant discharge permit effective until December 4, 2028, indicating compliance with environmental regulations[52]. - The company reported no exceedance of pollutant discharge limits for particulate matter, sulfur dioxide, and nitrogen oxides during the reporting period[53]. - The company invested CNY 1,756,892.22 in environmental protection and incurred expenses of CNY 9,537,524.09 during the reporting period[57]. - The company emphasizes sustainable development and has a dedicated department for safety production and environmental protection[60]. Financial Position and Assets - Total assets at the end of the reporting period were ¥2,283,808,534.15, a decrease of 1.16% from the end of the previous year[13]. - The company's total current assets decreased from CNY 1,857,319,421.76 to CNY 1,842,823,960.55, a decline of approximately 0.8%[93]. - Cash and cash equivalents dropped from CNY 486,901,359.23 to CNY 368,767,381.47, representing a decrease of about 24.3%[93]. - The company has established an ISO management system at its production base and a cGMP system at its U.S. facility, ensuring compliance with international pharmaceutical standards[22]. Shareholder and Equity Information - No cash dividends or stock bonuses will be distributed for this fiscal year, as the company aims to reinvest profits into growth initiatives[3]. - The company’s share capital structure changed, with the total number of shares increasing from 65,634,680 to 90,335,000, representing a 37.5% increase[79]. - Kingchem (China) Holding LLC holds 48.66% of the shares, totaling 58,609,282 shares, with an increase of 16,745,509 shares during the reporting period[83]. - The company plans to lift restrictions on 25,810,000 shares on August 7, 2024, as part of the equity distribution plan[82]. Risk Management - The company has identified potential risks including market competition and regulatory changes, and is implementing measures to mitigate these risks[3]. - The management emphasizes the importance of quality management, EHS management, and intellectual property management as critical factors for supplier selection in the pharmaceutical industry[22]. - The company faces intensified industry competition risks due to factors such as decoupling and significant investments in the domestic sector, prompting a strategic focus on leveraging its U.S. production base and existing customer resources[45]. Accounting and Financial Reporting - The financial statements reflect the company's financial position as of June 30, 2024, and the operating results and cash flows for the first half of 2024[124]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial reports are true and complete[124]. - The company recognizes revenue when control of goods or services is transferred to customers, typically at the point of sale[156]. - The company assesses the recoverability of deferred tax assets at each reporting date, reducing the carrying amount if future taxable income is unlikely[159].

证券代码：301509 证券简称：金凯生科 公告编号：2024-020 金凯（辽宁）生命科技股份有限公司 关于部分首次公开发行前已发行股份上市流通的 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为金凯（辽宁）生命科技股份有限公司（以下简称 "公司"或"金凯生科"或"发行人"）首次公开发行前已发行的部分股份。 2、本次解除限售股东户数共计7户，解除限售股份的数量为26,629,259股，占 公司发行后总股本的22.1088%。 3、本次解除限售的股份上市流通日期为2024年8月7日（星期三）。 一、首次公开发行股份及上市后股份变动概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意金凯（辽宁）生命科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕1115号）同意注册，并经深圳证 券交易所《关于金凯（辽宁）生命科技股份有限公司人民币普通股股票在创业板上 市的通知》（深证上〔2023〕685号）同意，金凯生科首次公开发行人民币普通股 （A股）股票21,508,335股，并于2023年 ...

中信建投证券股份有限公司 关于金凯（辽宁）生命科技股份有限公司 部分首次公开发行前已发行股份上市流通的核查意见 中信建投证券股份有限公司（以下简称"中信建投"、"保荐机构"）作为 金凯（辽宁）生命科技股份有限公司（以下简称"金凯生科"、"公司"）首次 公开发行股票并在创业板上市及持续督导的保荐机构，根据《证券发行上市保荐 业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市 公司自律监管指引第 13 号——保荐业务》等相关法律、法规和规范性文件的规 定，对金凯生科部分首次公开发行前已发行股份上市流通的事项进行了审慎核查， 具体核查情况如下： 一、首次公开发行股份及上市后股份变动概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意金凯（辽宁）生命科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2023〕1115 号）同意注册，并经深 圳证券交易所《关于金凯（辽宁）生命科技股份有限公司人民币普通股股票在创 业板上市的通知》（深证上〔2023〕685 号）同意，金凯生科首次公开发行人民 币普通股（ ...

证券代码：301509 证券简称：金凯生科 公告编号：2024-017 金凯（辽宁）生命科技股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形； 2、召开地点：金凯（辽宁）生命科技股份有限公司会议室。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2024 年 4 月 23 日（星期二）下午 14：00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2024 年 4 月 23 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00— 15:00；通过深圳证券交易所互联网系统投票的具体时间为 2024 年 4 月 23 日 9:15—15:00。 3、召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 4、召集人：公司董事会。 5、主持人：董事长 FUMIN WANG（王富民）先生。 6、本次会议的召集、召开符合《中华人民共和国公司法》《上市公 ...

一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 | | | 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 1 次 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | | | 4、公司治理督导情况 | | | （1）列席公司股东大会次数 | 0 次 | | （2）列席公司董事会次数 | 1 次 | | （3）列席公司监事会次数 | 次 1 | | 5、现场检查情况 | | | （1）现场检查次数 | 次 1 | | （2）现场检查报告是否按照本所规定报送 | 是 | | （3）现场检查发现的主要问题及整改情况 ...

北京市中伦（青岛）律师事务所 关于金凯（辽宁）生命科技股份有限公司 2023 年度股东大会的 法律意见书 二〇二四年四月 北京市中伦（青岛）律师事务所 关于金凯（辽宁）生命科技股份有限公司 2023 年度股东大会的 法律意见书 致：金凯（辽宁）生命科技股份有限公司 北京市中伦（青岛）律师事务所（以下简称"本所"）接受金凯（辽宁）生 命科技股份有限公司（以下简称"公司"）的委托，根据本法律意见书出具日前 已经发生或存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 《律师事务所从事证券法律业务管理办法》《律师事务所证券法律业务执业规则 （试行）》等中华人民共和国（以下简称"中国"，为本法律意见书之目的，不 包括香港特别行政区、澳门特别行政区和台湾地区）现行有效的法律、法规和 规范性文件以及《金凯（辽宁）生命科技股份有限公司章程》（以下简称"《公 司章程》"）、《金凯（辽宁）生命科技股份有限公司股东大会议事规则》（以下简 称"《股东大会议事规则》"）等有关规定，指派律师出席公司于 2024 年 4 月 23 日召开的 2023 ...

Financial Performance - The company's revenue for Q1 2024 was ¥124,332,621.75, a decrease of 41.87% compared to ¥213,889,447.06 in the same period last year[4] - Net profit attributable to shareholders was ¥16,741,205.71, down 58.83% from ¥40,666,713.67 year-on-year[4] - Basic and diluted earnings per share decreased by 69.84% to ¥0.19 from ¥0.63 in the same period last year[4] - Total operating revenue for Q1 2024 was CNY 124,332,621.75, a decrease of 41.8% compared to CNY 213,889,447.06 in the same period last year[20] - The net profit for Q1 2024 was CNY 16,741,205.71, a decrease of 58.8% compared to CNY 40,666,713.67 in Q1 2023[21] - Total operating income for Q1 2024 was CNY 20,066,982.38, down from CNY 49,009,645.28 in the same period last year[21] - The company reported a total comprehensive income of CNY 17,005,810.60 for Q1 2024, down from CNY 38,703,148.36 in Q1 2023[21] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥74,538,568.94, compared to a negative cash flow of ¥24,462,228.52 in the previous year, representing a 404.71% improvement[4] - Cash flow from operating activities generated a net amount of CNY 74,538,568.94, a significant improvement from a net outflow of CNY 24,462,228.52 in Q1 2023[23] - Cash and cash equivalents increased to CNY 536,014,618.49 from CNY 486,901,359.23, reflecting a growth of 10.4%[18] - Cash and cash equivalents at the end of Q1 2024 totaled CNY 536,014,618.49, compared to CNY 223,449,259.92 at the end of Q1 2023[24] - Operating cash inflows totaled CNY 181,469,978.88, an increase from CNY 141,122,526.44 in the previous year[23] - The company incurred total operating cash outflows of CNY 106,931,409.94, down from CNY 165,584,754.96 in Q1 2023[23] - The net cash flow from investing activities was negative CNY 21,447,108.10, compared to a positive CNY 38,011,094.89 in Q1 2023[23] - The company experienced a foreign exchange impact of CNY 1,074,957.31 on cash and cash equivalents during the quarter[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,295,075,903.84, a slight decrease of 0.67% from ¥2,310,635,609.21 at the end of the previous year[4] - Total assets decreased to CNY 2,295,075,903.84 from CNY 2,310,635,609.21, a decline of 0.7%[19] - Total liabilities decreased to CNY 105,693,583.02 from CNY 139,630,803.20, a reduction of 24.3%[19] - The company's total equity increased to CNY 2,189,382,320.82 from CNY 2,171,004,806.01, reflecting a growth of 0.8%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,569, with the largest shareholder holding 48.66% of the shares[10] - The company reported a total of 65,634,680 shares with 1,109,680 shares released from restrictions during the period, leaving 64,525,000 shares under restriction[13] - Kingchem (China) Holding LLC holds 41,863,773 shares, which are subject to a lock-up until February 3, 2027[13] - The top ten unrestricted shareholders include Bai Qingliang with 341,400 shares and Xingye Bank with 215,000 shares[11] - The company has a total of 7,500,000 shares held by Qilu (Xiamen) Equity Investment Partnership, which are also subject to a lock-up until August 3, 2024[13] - The company has no changes in the top ten shareholders due to securities lending or borrowing activities[11] - The total number of shares held by the top ten unrestricted shareholders is 1,109,680 shares, which were released from restrictions on February 5, 2024[13] - The company has a total of 3,933,911 shares held by Blue Economy Zone Industrial Investment Fund, which are subject to a lock-up until August 3, 2024[13] Operational Efficiency - The company experienced a 39.37% reduction in operating costs, which amounted to ¥75,352,404.76 compared to ¥124,289,242.50 in the previous year[8] - Total operating costs for Q1 2024 were CNY 110,839,890.09, down 32.3% from CNY 164,128,214.79 in the previous year[20] - Research and development expenses for Q1 2024 were CNY 6,964,404.48, down from CNY 8,197,380.38 in the previous year, indicating a decrease of 15.0%[20] - Accounts receivable decreased by 46.04% to ¥55,911,064.26, primarily due to the collection of large receivables from the beginning of the year[7] - Accounts receivable decreased significantly to CNY 55,911,064.26 from CNY 103,618,656.11, a reduction of 46.0%[18] Governance - The company held its first temporary shareholders' meeting on January 9, 2024, to elect the second board of directors and supervisory board[15] - The company has completed the election of its second board of directors and supervisory board, ensuring continuity in governance[15] - The company has no preferred shareholders or changes in restricted shares during the reporting period[12] Government Support and Investment - The company reported a significant increase in government subsidies, totaling ¥1,236,991.05, which is a 165.28% increase compared to ¥466,304.69 in the previous year[8] - Investment income rose to ¥1,596,683.03, marking an increase of 185.93% from ¥558,421.85 year-on-year[8] - The company reported a net profit of CNY 1,596,683.03 from investments, an increase compared to CNY 558,421.85 in the previous year[20]

中信建投证券股份有限公司 关于金凯（辽宁）生命科技股份有限公司 2023 年度持续督导定期现场检查报告 | 保荐机构名称：中信建投证券股份有限公司 | 被保荐公司简称：金凯生科 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 保荐代表人姓名：逯金才 | | | | | 联系电话：010-5605 2488 | | | 保荐代表人姓名：张林 | | | | | 联系电话：010-5605 1430 | | | 现场检查人员姓名：逯金才 | | | | | | | | 现场检查对应期间：2023 年度（金凯生科于 2023 年 8 月 | 日上市） | | | | 3 | | | 年 月 月 日 现场检查时间：2024 3 29 日-3 30 | | | | | | | | 一、现场检查事项 | | 现场检查意见 | | | | | | （一）公司治理 | 是 | | 不适用 | 否 | | | | 现场检查手段（包括但不限于本指引第 33 | | | | 条所列）：查阅公司章程、公司治理制度以及三会会 | | | | 议资料、信息披露文件等 | ...

Financial Performance - The company reported a revenue of RMB 500 million for the fiscal year 2023, representing a 20% increase compared to the previous year [24]. - The company's operating revenue for 2023 was ¥766,824,305.02, representing a 7.00% increase from ¥716,670,015.13 in 2022 [29]. - Net profit attributable to shareholders for 2023 was ¥173,574,166.37, up 7.51% from ¥161,450,526.85 in 2022 [29]. - The net profit after deducting non-recurring gains and losses was ¥167,843,305.36, a 9.45% increase from ¥153,346,604.86 in 2022 [29]. - The gross margin for the CDMO sector improved to 47.43%, an increase of 3.48% compared to the previous year [54]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth [105]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 25% [185]. Market Expansion and Growth Strategies - The company is focused on expanding its market presence and enhancing its service offerings in the life sciences sector [5]. - The company is expanding its market presence in Europe, targeting a 10% market share within the next two years [24]. - The company plans to enter two new international markets by the end of the next fiscal year [163]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years [185]. - The company is exploring partnerships with international pharmaceutical firms to enhance distribution channels [24]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals [163]. Research and Development - The company plans to increase its R&D budget by 15% in the upcoming year to support ongoing clinical trials [24]. - The company has invested RMB 50 million in new technology for drug formulation processes, improving efficiency by 30% [24]. - The company is investing in R&D, allocating 10% of its revenue, approximately 120 million RMB, to develop new technologies [105]. - The company is investing 200 million yuan in R&D for new technologies aimed at enhancing product efficacy and user experience [180]. - The company has a number of clinical-stage projects in its pipeline, which could lead to explosive growth if any of these products are approved for market [48]. Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and transparency in its operations [5]. - The company has established a comprehensive governance structure that complies with relevant laws and regulations, ensuring effective decision-making and oversight [94]. - The company has established independent decision-making and supervisory bodies, ensuring no interference from controlling shareholders [99]. - The company has a robust investor relations management system, ensuring timely and accurate information disclosure [96]. - The company has established a shareholder return plan for the next three years, emphasizing the importance of cash dividends [134]. Risks and Challenges - The company faces risks including service disconnection, demand fluctuations, intensified competition, and production safety issues [5]. - The company is exposed to foreign exchange risks, particularly fluctuations in the RMB/USD exchange rate, which can impact its sales revenue and foreign exchange gains or losses [88]. - Environmental and safety production pressures are increasing as the company expands its operations, posing risks related to equipment failures and compliance with safety measures [88]. - The company faces risks from intensified industry competition due to significant investments in the domestic CDMO sector and potential unfair advantages held by overseas competitors [88]. Sustainability and Environmental Initiatives - The company emphasizes its commitment to sustainability, aiming to reduce operational carbon emissions by 15% over the next three years [105]. - The company has implemented a green manufacturing strategy, significantly reducing waste emissions and energy consumption, and was awarded the title of "Green Factory" in 2023 [149]. - The company has established effective waste gas treatment processes, including high-temperature incineration and advanced filtration systems, to meet emission standards [150]. - The company has committed to sustainability initiatives, with plans to reduce carbon emissions by 30% over the next five years [185]. Shareholder Returns and Dividends - The company reported a cash dividend of 8.00 CNY per 10 shares, totaling approximately 68.83 million CNY for all shareholders [6]. - The cash dividend represents 100% of the total profit distribution amount, with no shares being distributed as redemptions [134]. - The company plans to distribute a cash dividend amounting to 15%, not exceeding 50% of the total cash dividends received since its listing [177]. Internal Controls and Audit - The internal control system is compliant with legal requirements and effectively supports the company's strategic implementation [138]. - The internal control audit report indicates that as of December 31, 2023, the internal controls related to financial statements were effectively maintained in all material aspects according to the Basic Norms for Enterprise Internal Control [142]. - The company has established a dedicated department for safety production and environmental protection, continuously investing in safety and environmental facilities and capabilities [159]. Employee Management and Structure - The total number of employees at the end of the reporting period is 808, including 758 at the parent company and 50 at major subsidiaries [129]. - The company has established a competitive salary system based on job value, individual capability, and performance, ensuring fairness internally and competitiveness externally [131]. - The company emphasizes employee rights protection, providing timely salary payments and various welfare benefits, including housing subsidies for college graduates [158].